CTx-1301 is a novel proprietary formulation of dexmethylphenidate, a stimulant that increases norepinephrine and dopamine activity in the brain.
Though ADHD is typically treated with stimulants like Adderall, people may opt for non-stimulants because they come with ...
Cingulate received a target date from the U.S. Food and Drug Administration for when it will know if one of its medications ...
TipRanks on MSN
Cingulate Inc’s NDA for CTx-1301 Accepted by FDA
Cingulate Inc ( ($CING) ) just unveiled an update. On October 14, 2025, Cingulate Inc. announced that the FDA has accepted the New Drug ...
Adderall is a stimulant medication that can improve focus and decrease restlessness in people with ADHD, but there are side ...
Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) , a leading medical device and technology company specializing in the development and commercialization of highly effective ...
(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN), Tuesday announced a licensing deal with M8 Pharmaceuticals to commercialize its ADHD drug Qelbree under the latter's trademark in Latin America.
ADHD affects millions across the lifespan, disrupting school, work and relationships. Once seen as a childhood disorder, it’s ...
Tylenol should be used judiciously. But given the risks posed by fevers and pain during pregnancy, it's the safest option for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback